Sinopharm (CNCM) reports revenue rise despite profit dip in 2024

Sinopharm Group Co. Ltd. (HKEX: 1099) announced the principal accounting data and financial indicators for its subsidiary, Sinopharm (CNCM) for the year 2024. Revenue reached RMB 50.597 billion, a 1.81% increase from RMB 49.696 billion in 2023. However, net profit attributable to shareholders decreased by 6.80% to RMB 2.000 billion from RMB 2.146 billion the previous year. Basic earnings per share also experienced a decline, falling to RMB 2.6509. Net cash flow from operating activities decreased significantly by 39.15% to RMB 1.659 billion. The announcement, dated March 19, 2025, attributes the decrease in net cash flow to market conditions, extended payment cycles, increased procurement pressure, and capital raising adjustments.